MedTrace Logo

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

NCT04435314 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-10-28

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease.

Conditions

  • covid19

Interventions

DRUG

Nitazoxanide

Subjects will receive nitazonanide 600 mg TID for 7 days

DRUG

Placebo

Subjects will receive placebo TID for 7 days.

Sponsors & Collaborators

  • Farmoquimica S.A.

    collaborator INDUSTRY

  • Azidus Brasil

    lead INDUSTRY

Principal Investigators

  • Reginaldo Raimundo Fujita · Federal University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2020-08-31
Completion
2020-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435314 on ClinicalTrials.gov